Finasteride 5-Alpha Reductase Inhibitor Research: DHT Suppression and Enzyme Kinetics
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Overview of Finasteride Mechanism
Finasteride (MW 372.55 g/mol, CAS 98319-26-7) is a type II 5-alpha reductase (5-AR) inhibitor that acts as a mechanism-based (suicide) inactivator, forming a stable NADP-finasteride complex with the enzyme active site. 5-AR type II (SRD5A2) converts testosterone to dihydrotestosterone (DHT) in target tissues; finasteride irreversibly inhibits this reaction in biochemical and cell-based assay systems.
The compound demonstrates exceptional selectivity for SRD5A2 over SRD5A1, with IC50 values of 6.2 nM and 680 nM respectively in human enzyme preparations. This 110-fold selectivity profile makes finasteride particularly valuable for investigating type II-specific 5-alpha reductase signalling pathways in cellular models.
5-Alpha Reductase Enzyme Kinetics Research
Microsomal Enzyme Preparations
5-AR type I (SRD5A1) and type II (SRD5A2) enzyme kinetics are characterised using microsomal preparations from transfected cell lines expressing individual isozymes. Human embryonic kidney (HEK293) cells stably transfected with SRD5A2 demonstrate robust enzyme activity with Km values for testosterone ranging from 0.8-2.1 μM, depending on assay conditions and membrane preparation methods.
Enzyme kinetic studies reveal finasteride exhibits time-dependent inhibition characteristics, with progressive inactivation occurring over 15-60 minute incubation periods. The apparent Ki value for initial binding is approximately 4.8 nM, while the kinact value representing the rate of irreversible inactivation is 0.033 min⁻¹.
NADPH Cofactor Requirements
5-Alpha reductase enzyme activity requires NADPH as an essential cofactor for the reduction reaction. In vitro assays typically employ NADPH concentrations ranging from 100-500 μM to achieve saturating conditions. Finasteride binding to the enzyme-NADPH complex prevents cofactor release, effectively sequestering the enzyme in an inactive state.
Steady-state kinetic analysis demonstrates competitive inhibition patterns with respect to testosterone substrate, while mixed inhibition occurs relative to NADPH cofactor. These kinetic profiles support the proposed mechanism involving finasteride binding to the enzyme-NADPH binary complex.
Cell-Based DHT Suppression Assays
Prostate Cell Models
LNCaP prostate adenocarcinoma cells endogenously express SRD5A2 and serve as validated models for studying DHT formation and suppression. In these cellular systems, finasteride treatment produces dose-dependent reductions in DHT accumulation with EC50 values of 8-15 nM when cells are incubated with testosterone substrate.
PC-3 prostate cancer cells transfected with SRD5A2 expression vectors provide additional model systems for investigating receptor-mediated responses to altered DHT levels. These engineered cell lines demonstrate enhanced sensitivity to finasteride inhibition compared to native expression models.
Scalp Dermal Papilla Cultures
Primary human dermal papilla cells isolated from scalp tissue express both SRD5A1 and SRD5A2 isoforms, though SRD5A2 predominates in these cellular populations. Finasteride treatment of dermal papilla cultures results in 70-85% suppression of DHT formation at concentrations above 100 nM.
Immunofluorescence studies demonstrate SRD5A2 localisation primarily in the endoplasmic reticulum and nuclear envelope regions of dermal papilla cells. Finasteride treatment does not alter subcellular enzyme distribution but effectively reduces measurable 5-alpha reductase activity in cellular fractionation studies.
Binding Affinity and Selectivity Studies
Radioligand Displacement Assays
[³H]-finasteride binding studies using membrane preparations from SRD5A2-expressing cells reveal saturable, high-affinity binding sites with Kd values of 3.2-4.8 nM. Binding saturation occurs at approximately 0.8-1.2 pmol/mg membrane protein, indicating relatively low enzyme expression levels in heterologous systems.
Competition binding experiments demonstrate finasteride's selectivity profile against related steroid molecules. The compound shows minimal binding affinity for androgen receptors (IC50 > 10 μM), progesterone receptors (IC50 > 25 μM), or glucocorticoid receptors (IC50 > 50 μM).
Structure-Activity Relationships
Structural modifications to finasteride's core steroid framework reveal critical molecular features required for 5-alpha reductase binding and inhibition. The 4-aza-3-oxo-5α-androst-1-ene structure maintains optimal geometry for enzyme active site recognition, while the tert-butyl carboxamide substituent contributes to binding specificity.
Research Summary
Finasteride represents a highly selective, irreversible inhibitor of SRD5A2 with well-characterised enzyme kinetics and cellular pharmacology profiles. Its mechanism-based inactivation properties and exceptional selectivity make it an valuable research tool for investigating 5-alpha reductase signalling pathways in various cell culture models. The compound's ability to suppress DHT formation with nanomolar potency enables precise modulation of androgen metabolism in biochemical and cellular assay systems.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
